Koželuhová Jana, Balihar Karel, Janská Eva, Fremundová Lucie, Matějovič Martin
Vnitr Lek. 2014 Jul-Aug;60(7-8):630-4.
The aim of this article is to objective review available research data regarding the safety of biological therapies during pregnancy and breastfeeding in women with inflammatory bowel disease. Biological therapies appear to be safe in pregnancy, as no increased risk of malformations has been demonstrated. Available clinical results suggest that the efficacy of infliximab and adalimumab in achieving clinical response and maintaining remission in pregnant patients might outweigh the theoretical risks of drug exposure to the fetus. If possible, anti-TNF therapy should be stopped by the end of the second trimester due to transplacental transfer and potential risk for the fetus. The use of infliximab and adalimumab is probably compatible with breastfeeding.
本文旨在客观回顾关于炎症性肠病女性在妊娠和哺乳期使用生物疗法安全性的现有研究数据。生物疗法在妊娠期间似乎是安全的，因为尚未证实存在畸形风险增加的情况。现有临床结果表明，英夫利昔单抗和阿达木单抗在实现妊娠患者临床反应和维持缓解方面的疗效可能超过药物暴露于胎儿的理论风险。如果可能，由于经胎盘转移和对胎儿的潜在风险，应在孕中期结束时停用抗TNF治疗。英夫利昔单抗和阿达木单抗的使用可能与母乳喂养相容。
